Cyberonics' CEO saves firm and dumps stocks

Cyberonics' cyclothymic, a device used as a treatment for epileptic seizures, shares went from 40 to 13 and back to 45 as the FDA did not back the proposal. With the approval of new data presented by Skip Cummins, chief executive to the FDA, the company is expected to reach $1billion in sales by 2010 and thereby become the industry leader in the next frontier for medical devices.